222 related articles for article (PubMed ID: 20478991)
1. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.
Mushtaq S; Warner M; Williams G; Critchley I; Livermore DM
J Antimicrob Chemother; 2010 Jul; 65(7):1428-32. PubMed ID: 20478991
[TBL] [Abstract][Full Text] [Related]
2. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Ge Y
J Antimicrob Chemother; 2010 Sep; 65(9):1972-4. PubMed ID: 20595207
[TBL] [Abstract][Full Text] [Related]
3. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.
Livermore DM; Mushtaq S; Warner M; Miossec C; Woodford N
J Antimicrob Chemother; 2008 Nov; 62(5):1053-6. PubMed ID: 18689875
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
5. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Warner M; Zhang J; Maharjan S; Doumith M; Woodford N
Antimicrob Agents Chemother; 2011 Jan; 55(1):390-4. PubMed ID: 21041502
[TBL] [Abstract][Full Text] [Related]
6. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).
Livermore DM; Mushtaq S; Barker K; Hope R; Warner M; Woodford N
J Antimicrob Chemother; 2012 Jun; 67(6):1354-8. PubMed ID: 22441578
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
Mushtaq S; Warner M; Livermore DM
J Antimicrob Chemother; 2010 Nov; 65(11):2376-81. PubMed ID: 20801783
[TBL] [Abstract][Full Text] [Related]
8. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
Castanheira M; Sader HS; Farrell DJ; Mendes RE; Jones RN
Antimicrob Agents Chemother; 2012 Sep; 56(9):4779-85. PubMed ID: 22733066
[TBL] [Abstract][Full Text] [Related]
9. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.
Livermore DM; Warner M; Mushtaq S
J Antimicrob Chemother; 2013 Oct; 68(10):2286-90. PubMed ID: 23696619
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
Wiskirchen DE; Crandon JL; Furtado GH; Williams G; Nicolau DP
Antimicrob Agents Chemother; 2011 Jul; 55(7):3220-5. PubMed ID: 21518838
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.
Stachyra T; Levasseur P; Péchereau MC; Girard AM; Claudon M; Miossec C; Black MT
J Antimicrob Chemother; 2009 Aug; 64(2):326-9. PubMed ID: 19493866
[TBL] [Abstract][Full Text] [Related]
12. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
13. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
15. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.
Louie A; Castanheira M; Liu W; Grasso C; Jones RN; Williams G; Critchley I; Thye D; Brown D; Vanscoy B; Kulawy R; Drusano GL
Antimicrob Agents Chemother; 2012 Jan; 56(1):258-70. PubMed ID: 22024819
[TBL] [Abstract][Full Text] [Related]
17. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
18. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
Livermore DM; Hope R; Mushtaq S; Warner M
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
[TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
Susić E
Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
